Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study

Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study

Purpose: To describe the clinical and pathologic characteristics of a case of retinal vasculitis and vitritis following brolucizumab administration and subsequent ranibizumab treatment. Observations: A 76-year old Caucasian woman experienced pain, decreased vision and floaters one week after receivi...

Full description

Bibliographic Details
Main Authors:	Prashanth G. Iyer, Marc C. Peden, Ivan J. Suñer, Nish Patel, Sander R. Dubovy, Thomas A. Albini
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	American Journal of Ophthalmology Case Reports
Subjects:	Brolucizumab Retinal vasculitis Intraocular inflammation Cytopathology Hypersensitivity reaction Age-related macular degeneration
Online Access:	http://www.sciencedirect.com/science/article/pii/S2451993620303042

Similar Items

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
by: Sara J. Haug, et al.
Published: (2020-06-01)

Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting
by: Dilraj S. Grewal, MD, et al.
Published: (2024-01-01)

Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema
by: Takao Hirano, et al.
Published: (2023-03-01)

Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis
by: Saba NJ, et al.
Published: (2023-09-01)

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
by: Debdulal Chakraborty, et al.
Published: (2023-01-01)

Scleritis following intravitreal brolucizumab injection: a case series
by: Takuya Takayama, et al.
Published: (2024-02-01)

Real-world experience of brolucizumab in nAMD
by: Shilpi H Narnaware, et al.
Published: (2024-01-01)

Bilateral blindness after uneventful brolucizumab injection for macular degeneration
by: Ilan Barchichat, et al.
Published: (2022-02-01)

Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report
by: Eun Kyoung Lee, et al.
Published: (2022-06-01)

Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review
by: Justus G. Garweg, et al.
Published: (2023-07-01)

Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection
by: Yoshiki Ueta, et al.
Published: (2023-11-01)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
by: Ryan Zubricky, et al.
Published: (2023-06-01)

Vitreous Noise on Optical Coherence Tomography as an Early Finding of Brolucizumab-Related Intraocular Inflammation
by: Yuji Yoshikawa, et al.
Published: (2021-09-01)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
by: Yoshiko Fukuda, et al.
Published: (2021-09-01)

Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment
by: Natsuki Ueji, et al.
Published: (2023-10-01)

Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation
by: Sentaro Kusuhara, et al.
Published: (2022-06-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
by: Justus G. Garweg, et al.
Published: (2023-01-01)

Hypersensitivity vasculitis induced by cefoperazone/sulbactam
by: Ariturk Ender, et al.
Published: (2003-01-01)

A case of intraocular inflammation after intravitreal brolucizumab injection monitored by laser flare-cell photometer
by: Masaaki Saito, et al.
Published: (2022-12-01)

Side Effects of Brolucizumab
by: Tahmineh Motevasseli, et al.
Published: (2021-10-01)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
by: Christof Haensli, et al.
Published: (2021-06-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study
by: DebdulalChakraborty, et al.
Published: (2022-01-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
by: Chakraborty D, et al.
Published: (2021-09-01)

Advanced Coats’ disease treated with intravitreal brolucizumab combined with laser photocoagulation
by: Nimesh A. Patel, et al.
Published: (2020-09-01)

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
by: Ryo Mukai, et al.
Published: (2022-09-01)

Cefoperazone induced hypersensitivity vasculitis
by: Katiyar Subodh, et al.
Published: (2009-01-01)

KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema
by: Wykoff, Charles C., et al.
Published: (2024)

Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature
by: Ivana Pantic, et al.
Published: (2022-01-01)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022-05-01)

Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
by: Ha Eun Sim, et al.
Published: (2022-03-01)

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
by: Nadia Zakaria, et al.
Published: (2022-04-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
by: Chakraborty D, et al.
Published: (2022-12-01)

NSAIDs linked to IgA-mediated hypersensitivity vasculitis and purpura fulminans-like eruption
by: Guy Levenberg, et al.
Published: (2023-10-01)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
by: Emilia Maggio, et al.
Published: (2022-09-01)

Role of intravitreal brolucizumab with intravitreal rtPA and pneumatic displacement for submacular hemorrhage: A case series
by: Debdulal Chakraborty, et al.
Published: (2022-03-01)

Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies
by: Karasavvidou EM, et al.
Published: (2022-08-01)

One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment
by: Hironori Takahashi, et al.
Published: (2024-04-01)

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series
by: Debdulal Chakraborty, et al.
Published: (2022-11-01)

Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection
by: Somnath Chakraborty, et al.
Published: (2023-06-01)